These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 20586711)

  • 1. Targeting epidermal growth factor receptor in the treatment of non-small-cell lung cancer.
    Kotsakis A; Georgoulias V
    Expert Opin Pharmacother; 2010 Oct; 11(14):2363-89. PubMed ID: 20586711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-line treatment for advanced nonsmall cell lung cancer harboring activating epidermal growth factor receptor mutation: epidermal growth factor receptor tyrosine kinase inhibitors or chemotherapy?
    Gridelli C
    Curr Opin Oncol; 2011 Mar; 23(2):131-2. PubMed ID: 21307676
    [No Abstract]   [Full Text] [Related]  

  • 3. Targeting non-small cell lung cancer with epidermal growth factor tyrosine kinase inhibitors: where do we stand, where do we go.
    Patel JD; Pasche B; Argiris A
    Crit Rev Oncol Hematol; 2004 Jun; 50(3):175-86. PubMed ID: 15182824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
    Jänne PA; Johnson BE
    Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4416s-4420s. PubMed ID: 16857820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors.
    John T; Liu G; Tsao MS
    Oncogene; 2009 Aug; 28 Suppl 1():S14-23. PubMed ID: 19680292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermal growth factor receptor mutations detected by denaturing high-performance liquid chromatography in nonsmall cell lung cancer: impact on response to therapy with epidermal growth factor receptor-tyrosine kinase inhibitors.
    Cohen V; Agulnik JS; Ang C; Kasymjanova G; Batist G; Small D; Brandao G; Chong G; Miller WH
    Cancer; 2010 Sep; 116(18):4309-17. PubMed ID: 20549828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Personalized medicine for non-small-cell lung cancer.
    Mok TS; Zhou Q; Leung L; Loong HH
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1601-11. PubMed ID: 20942631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic polymorphisms of the epidermal growth factor and related receptor in non-small cell lung cancer--a review of the literature.
    Araújo A; Ribeiro R; Azevedo I; Coelho A; Soares M; Sousa B; Pinto D; Lopes C; Medeiros R; Scagliotti GV
    Oncologist; 2007 Feb; 12(2):201-10. PubMed ID: 17296816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors.
    Bonomi PD; Buckingham L; Coon J
    Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4606-12. PubMed ID: 17671150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Searching for a magic bullet in NSCLC: the role of epidermal growth factor receptor mutations and tyrosine kinase inhibitors.
    Wong KK
    Lung Cancer; 2008 Jun; 60 Suppl 2():S10-8. PubMed ID: 18513579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EGFR gene status in cytological samples of nonsmall cell lung carcinoma: controversies and opportunities.
    da Cunha Santos G; Saieg MA; Geddie W; Leighl N
    Cancer Cytopathol; 2011 Apr; 119(2):80-91. PubMed ID: 21400669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of serum hepatocyte growth factor on treatment response to epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small cell lung adenocarcinoma.
    Kasahara K; Arao T; Sakai K; Matsumoto K; Sakai A; Kimura H; Sone T; Horiike A; Nishio M; Ohira T; Ikeda N; Yamanaka T; Saijo N; Nishio K
    Clin Cancer Res; 2010 Sep; 16(18):4616-24. PubMed ID: 20679350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relevance of epidermal growth factor receptor genomic gain in predicting clinical response to kinase inhibitors in non-small-cell lung cancer.
    Reddy GK
    Clin Lung Cancer; 2005 Nov; 7(3):163-5. PubMed ID: 16354309
    [No Abstract]   [Full Text] [Related]  

  • 14. Individualizing therapy for non-small-cell lung cancer: a paradigm shift from empiric to integrated decision-making.
    Gandara DR; Lara PN; Mack P; Scagliotti G
    Clin Lung Cancer; 2009 May; 10(3):148-50. PubMed ID: 19443333
    [No Abstract]   [Full Text] [Related]  

  • 15. Epidermal growth factor receptor mutations and tyrosine kinase inhibitor therapy in advanced non-small-cell lung cancer.
    Technol Eval Cent Assess Program Exec Summ; 2011 Mar; 25(6):1-5. PubMed ID: 21638942
    [No Abstract]   [Full Text] [Related]  

  • 16. Epidermal growth factor receptor mutations and tyrosine kinase inhibitor therapy in advanced non-small-cell lung cancer.
    Technol Eval Cent Assess Program Exec Summ; 2007 Nov; 22(6):1-3. PubMed ID: 18080406
    [No Abstract]   [Full Text] [Related]  

  • 17. Epidermal growth factor receptor (EGFR) signaling and covalent EGFR inhibition in lung cancer.
    Heuckmann JM; Rauh D; Thomas RK
    J Clin Oncol; 2012 Sep; 30(27):3417-20. PubMed ID: 22915655
    [No Abstract]   [Full Text] [Related]  

  • 18. Targeting EGFR mutation in non-small-cell lung cancer: challenges and future perspectives.
    Haddad FG; Kourie HR; Kattan J
    Future Oncol; 2017 Feb; 13(3):201-204. PubMed ID: 27624407
    [No Abstract]   [Full Text] [Related]  

  • 19. Using EGFR status to personalize treatment: lung cancer researchers reach a milestone.
    Friedrich MJ
    J Natl Cancer Inst; 2009 Aug; 101(15):1039-41. PubMed ID: 19638503
    [No Abstract]   [Full Text] [Related]  

  • 20. Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of epidermal growth factor receptor-mutant non-small cell lung cancer metastatic to the brain.
    Jamal-Hanjani M; Spicer J
    Clin Cancer Res; 2012 Feb; 18(4):938-44. PubMed ID: 22167408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.